132 related articles for article (PubMed ID: 22410458)
1. Vascular disrupting agents: a delicate balance between efficacy and side effects.
Hollebecque A; Massard C; Soria JC
Curr Opin Oncol; 2012 May; 24(3):305-15. PubMed ID: 22410458
[TBL] [Abstract][Full Text] [Related]
2. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
3. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Horsman MR; Bohn AB; Busk M
Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
[TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
Baguley BC
Clin Lung Cancer; 2011 Mar; 12(2):81-6. PubMed ID: 21550553
[TBL] [Abstract][Full Text] [Related]
5. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
6. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
7. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
8. Vascular-disrupting agents in oncology.
Mita MM; Sargsyan L; Mita AC; Spear M
Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
[TBL] [Abstract][Full Text] [Related]
9. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
Gadgeel SM
Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
[TBL] [Abstract][Full Text] [Related]
10. Classification and toxicities of vascular disrupting agents.
Hasani A; Leighl N
Clin Lung Cancer; 2011 Jan; 12(1):18-25. PubMed ID: 21273175
[TBL] [Abstract][Full Text] [Related]
11. Antivascular agents for non-small-cell lung cancer: current status and future directions.
Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
13. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
[TBL] [Abstract][Full Text] [Related]
15. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Sangha R; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
[TBL] [Abstract][Full Text] [Related]
16. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis for the treatment of sarcoma.
Balasubramanian L; Evens AM
Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
[TBL] [Abstract][Full Text] [Related]
18. [New strategies for NSCLC: is inhibition of tumour vasculature useful].
Reinmuth N; Steins M; Kreuter M; Thomas M
Pneumologie; 2010 Jun; 64(6):376-86. PubMed ID: 20229453
[TBL] [Abstract][Full Text] [Related]
19. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
20. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]